The immunotherapy atezolizumab (Tecentriq, Genentech) demonstrated clinical benefit in advanced non-small cell lung cancer (NSCLC) in a study that extended the previous follow-up duration of primary studies (J Thorac Oncol 2016;11[11S]:S251-S252, PMID: 27969443).
In primary analyses, investigators with the BIRCH trial, a single-arm Phase II study of atezolizumab as first-line or subsequent therapy in programmed death ligand-1 (PD-L1)–selected advanced NSCLC, found an overall response rate